This study looked at two specific patients and reviewed nine other reported cases of primary malignant melanoma of the cervix. These patients received various treatments, including radical surgery, chemotherapy, and drugs called PD-1 or PD-L1 inhibitors. The goal was to understand how these rare cancers respond to current medical approaches.
The findings were mixed. One patient died from recurrence 36 months after surgery without additional therapy. Another patient showed significant tumor regression after receiving a combination of surgery, chemotherapy, and immunotherapy. However, a review of the literature showed that 80% of patients experienced disease progression when treated with immunotherapy alone.
Safety and limitations were significant concerns. PD-L1 expression was assessed in only three cases and did not reliably predict who would respond to treatment. High recurrence rates were observed even after surgery. Because the disease is so rare, there are no standardized treatment guidelines to follow.
Readers should take away that multimodal strategies combining surgery, chemotherapy, and other agents may offer some benefit. However, the inconsistent response to immune checkpoint inhibitors means this approach is not guaranteed to work for everyone. More research is needed before these findings can change standard practice.